Best Stocks To Buy Right Now

NEW YORK (TheStreet) -- The world is so awash in liquidity that big banks may soon feel forced to charge some of their customers for taking deposits.

The excess liquidity might be news to consumers who find themselves highly "illiquid" in tough economic times, but the Federal Reserve's "highly accommodative stance of monetary policy" has consequences, especially for savers.

As the economy has gone through its ups and downs, depositors over the past several decades have seen radical changes in how banks work to gather deposits, or turn them away. Depending on how old you are, you might remember banks giving away toasters and other goodies to new depositors. My sister and I received nifty little transistor radios when our parents opened savings passbook accounts for each of us during the 1970s.

Top 10 Diversified Bank Stocks To Invest In 2015: Manitex International Inc.(MNTX)

Manitex International, Inc. provides engineered lifting solutions. The company operates through two segments, Lifting Equipment and Equipment Distribution. The Lifting Equipment segment designs, manufactures, and distributes boom trucks and crane products that are primarily used for industrial projects and energy exploration, as well as for infrastructure development, including, roads, bridges, and commercial construction; and specialized rough terrain cranes and material handling products for the construction, municipality, and railroad industries. This segment also provides rough terrain forklifts for use in commercial and military applications; special mission oriented vehicles; and other specialized carriers, heavy material handling transporters, and steel mill equipment, as well as offers specialized custom trailers and hauling systems used for transporting heavy equipment. The Equipment Distribution segment distributes rough terrain and truck cranes, material handler s, boom trucks, and sky cranes for infrastructure development and commercial construction; supplies repair parts for various medium to heavy duty construction equipment; markets used lifting and construction equipment; and offers repair services. This segment sells its products to end users, including the rental market. Manitex International sells its products primarily in the United States, Canada, Algeria, the United Arab Emirates, Brazil, Italy, Korea, Mexico, China, Russia, Spain, Turkey, Puerto Rico, the Netherlands, Indonesia, and Chile. The company was formerly known as Veri-Tek International, Corp. and changed its name to Manitex International, Inc. in May 2008. Manitex International was founded in 1993 and is based in Bridgeview, Illinois.

Advisors' Opinion:

• [By James Brumley]

  Value fans also will love XRX’s forward-looking P/E of roughly 10.

  Manitex International (MNTX)

  12/2 Price: $13.28

  There might be nothing special about an obscure crane manufacturer at first glance, but a closer inspection of Manitex International (MNTX) reveals this company is driving some serious sales and earnings growth now that it has found its niche. Profits should be up 33% next year.

• [By Zacks Investment Research]

  1. Manitex International, Inc. (MNTX)
  

  Manitex manufactures lifting solutions including cranes, reach stackers and container handling equipment, rough terrain forklifts, and indoor electric forklifts. Headquartered in Illinois, it supplies crane parts to customers throughout the world.

Best Stocks To Buy Right Now: Treehouse Foods Inc.(THS)

TreeHouse Foods, Inc. operates as a food manufacturer in the United States and Canada. The company?s products include non-dairy powdered creamers; private label canned soups; salad dressings and sauces; powdered drink mixes; and hot cereals, such as oatmeal, farina, and grits in single-serve instant packets and microwaveable bowls. It also offers macaroni and cheese; skillet dinners; Mexican and other sauces comprising salsa, picante, cheese dip, enchilada sauce, pasta sauce, and taco sauce; jams and pie fillings; pickles and related products, including peppers and pickled vegetables; aseptic products, such as cheese sauces and puddings; and refrigerated salad dressings and liquid non-dairy creamer products. The company offers pickles under the Farman?s, Nalley?s, Peter Piper, and Steinfeld brand names; sauces and syrups under the Bennett?s, Hoffman House, Roddenbery?s Northwoods, and San Antonio Farms brand names; non-dairy powdered creamer under the Cremora brand na me; refrigerated products under the Mocha Mix and Second Nature brand names; jams and other sauces under the E.D. Smith and Habitant brand name; oatmeal under the McCann?s brand name; and food away from home products under the Schwartz and Saucemaker brands. It primarily serves grocery retailers, mass merchandisers, and foodservice operators through various distribution channels, including retail grocery; foodservice distributors; and industrial and export channels comprising food manufacturers and repackagers of foodservice products. TreeHouse Foods, Inc. was founded in 1862 and is based in Oak Brook, Illinois.

Advisors' Opinion:

• [By Jayson Derrick]

  Analysts at Citigroup maintained a Buy rating on Treehouse Foods (NYSE: THS) with a price target raised to $100 from a previous $93. Shares gained 3.12 percent, closing at $83.50.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Treehouse Foods (NYSE: THS  ) , whose recent revenue and earnings are plotted below.

• [By Vinay Singh]

  On the other hand, food manufacturer TreeHouse Foods (THS) has witnessed higher demand for its products. Its fourth-quarter revenue surged 11.4% over last year as revenue clocked in at $660.3 million. The acquisitions of Cains Foods and Associated Brands last year and an increase in volumes drove this revenue gain. The company also recently acquired Associated Brands, which added to its private-label food product portfolio. Also, TreeHouse's launch of specialty teas enabled it to expand its single-serve coffee business. Hence, this company provides tough competition to other food players.

Best Stocks To Buy Right Now: Advantest Corp (ATE)

Advantest Corporation, incorporated in December 1954, is a part of Advantest group. The Company operates in three segments: semiconductor and component test system segment; mechatronics system segment, focusing on peripheral devices including test handlers and device interfaces, and services, support and others segment. The semiconductor and component test system segment provides customers with test system products for the semiconductor industry and the electronic component industry. The mechatronics system segment focuses on peripheral devices to the semiconductor and component test systems. The services, support and others segment consists of comprehensive customer solutions provided in connection with the semiconductor and component test system and mechatronics system segments, support services and an equipment lease business.

Semiconductor and Component Test Systems Segment

Semiconductor and component test systems are used during the semiconductor and electronic component manufacturing process to confirm that a semiconductor functions properly. Semiconductor and component test systems consist of test systems for memory semiconductors and test systems for non memory semiconductors. Advantest�� test systems for memory semiconductors are test systems designed to test high-speed/high performance dynamic random access memory (DRAM) semiconductors used in equipment such as personal computers and servers, as well as flash memory semiconductors used in digital consumer products.

Test systems for memory semiconductors consist of a mainframe and one or more test heads. During testing, a device interface is attached to the test head. During the front-end testing process, wafers are loaded by a prober and are connected to the test system for memory semiconductors through the device interface. Electric signals between the die and the test systems for memory semiconductors are transmitted through probe pins located in the device interface and tested. After front-end te! sting is completed, the wafer is diced into separate dies and properly functioning dies are packaged. During back-end testing, test handlers are used to load these packaged devices onto the test heads, and electric signals are transmitted between the devices and the test heads via the device interface and tested. The test results are analyzed by the test systems for memory semiconductors��hardware circuits and software programs. Customized software programs for each semiconductor are required to analyze the semiconductor tests and test data.

Advantest�� main product lines of test systems for memory semiconductors are the T5500 series, the T5300 series and the T5700 series. The T5593 is a test system targeted at the market for high speed memory semiconductors, such as DDR2- Synchronous Dynamic Random Access Memory (SDRAM) and Synchronous Graphics Random Access Memory (SGRAM). The T5383 is a multi-functional test system for memory semiconductors that reduces testing costs for semiconductor manufacturers. Advantest�� main line of test systems for non memory semiconductors relates to test systems for SoC semiconductors, test systems for liquid crystal display (LCD) driver integrated circuits and test systems for semiconductors used in car electronics. The T6577 test systems for SoC semiconductors in the T6500 series were primarily developed to test micro controller unit (MCU) and SoC semiconductors that control digital consumer products at the production lines. The T6300 series are test systems for LCD driver integrated circuits used with high-definition LCD displays. The T7721, T7722 and T7723 are test systems for non memory semiconductors for mixed signal integrated circuits. The T8571A is a test system for non memory semiconductors that is primarily used to evaluate and analyze CCDs which are image sensors.

Mechatronics System Segment

The Main products in the Mechatronics System Segment are test handlers which handle semiconductor devices and automate the te! sting, an! d device interfaces which are the interfaces with devices being tested. Test handlers are used with semiconductor and component test systems to handle, condition temperature, contact and sort semiconductors and other electronic components during the back-end testing of the semiconductor manufacturing process. Advantest�� test handlers are sold primarily in conjunction with the sale of its semiconductor and component test systems. The M6242 test handler for test systems for memory semiconductors, including DDR-3SDRAM, can handle up to 512 semiconductors at a time. Advantest�� test handlers for non memory semiconductors, including SoC semiconductors, are the M4841, the M4741A and the M4742A, among others.

Advantest develops and manufactures device interfaces for semiconductor and component test systems and supplies device interfaces, such as high performance and high density connectors, socket boards and sockets. For test systems for memory semiconductors, Advantest provides motherboards capable of handling a maximum of 512 semiconductors at a time. For test systems for non memory semiconductors, Advantest provides motherboards that are compatible with a maximum of 3,072 signals. Advantest also provides motherboards designed for use in front-end testing. Advantest provides custom manufacturing of socket boards and performance boards for each device under test in accordance with customers��specifications.

Advantest provides sockets for test systems for memory semiconductors. Advantest provides low-inductance (0.4nH) sockets and fine pitch (0.4mm) sockets for semiconductors that are becoming more high-speed and more compact in size. Advantest provides carrying and contacting mechanism components compatible with each device under test for test handlers for memory semiconductors and test handlers for non memory semiconductors.

Services, Support and Others Segment

In the services, support and others segment, Advantest has focused on maintenance serv! ices, suc! h as installation and repair of Advantest�� products. It also focused on lease and rental services of its products as a part of Advantest�� effort to provide customers with comprehensive solutions.

The Company competes with Teradyne, Inc., Verigy Ltd., LTX-Credence Corporation, Yokogawa Electronic Corporation, FROM30 CO., LTD., EXICON Ltd., UniTest Inc., Delta Design, Inc., Seiko Epson Corporation, Mirae Corporation, TechWing, Inc., TSE Co., Ltd. and Secron Co., Ltd.

Advisors' Opinion:

• [By Dan Carroll]

  Nissan's done better this year than electronics maker Advantest (NYSE: ATE  ) , but this stock absolutely blew up over the past week. Advantest's shares shot higher by more than 9%, wiping out pessimism over the company's weak earnings released a few weeks ago. Advantest's net loss and operating profit both fell below its guidance, and despite this week's investor optimism, the future's murky for this company. Financial site TheStreet downgraded the stock last week, citing Advantest's falling earnings, among other issues.

Best Stocks To Buy Right Now: Lanxess AG (LXS)

Lanxess AG is a Germany-based chemical holding company. Its activities are divided into three main segments. The Performance Polymers segment encompasses the activities of the Lanxess Group in the production of rubber and plastics, and includes Butyl Rubbers, Performance Butadiene Rubbers, Technical Rubber Products and Semi-Crystalline Products business units. The Advanced Intermediates segment is engaged in the development, production and marketing of industrial and fine chemicals and includes Basic Chemicals and Saltigo business units. The Performance Chemicals segment combines the Group's application-oriented activities in the field of process and functional chemicals, and includes Material Protection Products, Inorganic Pigments, Functional Chemicals, Leather, Rhein Chemie, Rubber Chemicals and Ion Exchange Resins business units. The Company operates worldwide through its subsidiaries. Advisors' Opinion:

• [By Jonathan Morgan]

  Lanxess AG (LXS), which makes specialty chemicals, plastics, and rubber used in car tires, jumped 6.6 percent to 57.21 euros. Michelin & Cie, Europe�� largest tiremaker, today reiterated its 2013 profit forecast as growing demand for high-margin tires for mining vehicles helps offset declining demand in Europe.

• [By Sofia Horta e Costa]

  ThyssenKrupp AG (TKA), Germany�� largest steelmaker, rose to a five-week high. YOC AG (YOC) surged the most in more than three months after the mobile-phone advertising company said it sold 1.3 million euros ($1.7 million) of shares to increase capital. Lanxess AG (LXS), the chemical maker that joined the DAX in September, retreated 3.4 percent.

Best Stocks To Buy Right Now: Prana Biotechnology Ltd (PRAN)

Prana Biotechnology Limited engages in the research and development of therapeutic drugs for the treatment of neurological disorders in Australia. The company primarily focuses on the Alzheimer�s, Parkinson�s, and Huntington�s diseases, as well as various cancer, age-related macular degeneration and cataract, Motor Neuron, and Creutzfeldt-Jakob diseases. Its development stage product line comprises PBT2, a Phase IIb clinical trial product for the treatment of Alzheimer�s disease; and PBT2, a Phase IIa clinical trial product for the treatment of Huntington�s disease. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.

Advisors' Opinion:

• [By Bryan Murphy]

  Considering Eli Lilly & Co. (NYSE:LLY) as well as a co-development project between Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE) both failed in semi-recent effort to develop a similar-functioning Alzheimer's drug, it would be easy to assume that particular route towards an Alzheimer's might be the wrong path to take. Sometimes though, a small tweak or a seemingly-minor nuance with the underlying problem can make all the difference. Enter Prana Biotechnology Limited (NASDAQ:PRAN). Though the company acknowledges its focal point on the development of an Alzheimer's therapy is the same broad premise that ultimately led LLY, PFE, and JNJ to failure, PRAN may have found the proverbial missing link.

• [By James Brumley]

  SGNT stock is also valued at a palatable trailing P/E of 19.8, and has logged six straight quarterly earnings beats, making it one of the best cheap stocks in the pharmaceutical industry.

  Prana Biotechnology (PRAN)

  It’s a slippery slope when you start placing bets based on a company with no marketable product, and a lead candidate that’s only in Phase 2 trials. But, Prana Biotechnology (PRAN) may be one of those cheap stocks within the drugmaking world that’s worth the risk.

• [By John Udovich]

  The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:

Best Stocks To Buy Right Now: Avanir Pharmaceuticals Inc(AVNR)

Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The company primarily offers NUEDEXTA, a unique proprietary combination of dextromethorphan and low-dose quinidine for the treatment of pseudobulbar affect. Its product line also comprises AVP-923 in Phase II clinical trial for the treatment of central neuropathic pain in patients with multiple sclerosis; and in Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. In addition, the company provides Docosanol 10% cream, an over-the-counter product for cold sores treatment. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.

Advisors' Opinion:

• [By Rebecca McClay]

  Finally, Avanir Pharmaceuticals Inc. (Nasdaq: AVNR) is up about 7% today after it settled with Actavis South Atlantic and Actavis Inc. (NYSE: ACT) to resolve pending patent litigation regarding ACT's seeking approval to market generic versions of AVNR's NUEDEXTA capsules. ACT is up about 1%.

• [By Bryan Murphy]

  This is NOT a judgment call on the drug. This isn't a judgment call on the company either. This is a judgment call on how emotional and distracted traders can get from time to time, and we only have to look at Antares Pharma Inc. (NASDAQ:ATRS), Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), and VIVUS, Inc. (NASDAQ:VVUS) to see how drinking the proverbial Kool-Aid ultimately punished anyone who bought rather than sold ATRS, VVUS, and AVNR right when the news seemed to incredibly encouraging.

• [By Sean Williams]

  The end of the week brought fantastic news for shareholders in Avanir Pharmaceuticals (NASDAQ: AVNR  ) who witnessed the CHMP recommending approval for Nuedexta, it's already U.S.-approved treatment for psuedobulbar affect. An approval in Europe would be a key win for Avanir as Nuedexta currently makes up the majority of its revenue. In addition, it's worth noting that the European Medicine Agency's panel recommended two dosing regimens, potentially broadening in patient reach. Shares reacted notably higher but tapered off by the end of the day on Friday. Although the EMA isn't required to follow the recommendation of its panel, this would be a case where I'd be mildly surprised if it didn't.

• [By Sean Williams]

  On Wednesday, Avanir Pharmaceuticals (NASDAQ: AVNR  ) received good news from the Food and Drug Administration, which OK'd an accelerated development pathway for pre-investigational neuropathic pain drug AVP-786. The accelerated approval was based on data from AVP-923 and will allow Avanir to conduct minimal preclinical testing before advancing onto human trials. This saves the company time and, more importantly, precious cash. I would, however, caution against getting too excited, as even this accelerated development puts this drug, which isn't even in clinical trials yet, years away from a possible approval.